Agilent Technologies Inc.

Collaboration aimed at accelerating R&D in both small- and large-molecule analysis and building high-impact capabilities in fast-growing Asian markets

KUALA LUMPUR, Malaysia, Dec. 5, 2025 /PRNewswire/ -- Agilent Technologies Inc. (NYSE: A) announced the expansion of their strategic collaboration with Monash University in Malaysia to establish a state-of-the-art MUMPMP-Agilent BioDiscovery Hub aimed at accelerating regional biotechnology research and innovation. The new Memorandum of Understanding (MOU) was signed as part of the celebration of their 15-year strategic partnership, underscoring Agilent's continued commitment to advancing high-impact R&D capabilities in fast-growing Asian markets.

Under the renewed agreement, Agilent will place its high-resolution Revident Quadrupole Time of Flight LC/MS systems, coupled with 1290 Infinity III High-Performing LC series, and the next-generation 5977C Gas Chromatography/MSD, at the new hub to support mutually agreed research programs, applications development, workshops, and scientific training. This collaboration is designed to accelerate R&D in both small- and large-molecule analysis, enabling deeper insights across biomedical, pharmaceutical, and molecular biology fields.    

"This collaboration reflects Monash University Malaysia's commitment to delivering world-class research infrastructure that advances discovery and benefits our communities. The MUMPMP–Agilent BioDiscovery Hub strengthens Monash's position as a regional leader in proteomics, metabolomics, and biotechnology innovation. By combining Agilent's state-of-the-art technologies with Monash's research excellence and multidisciplinary ecosystem, we are empowering our scientists and partners to drive impactful solutions for Malaysia and the Asia-Pacific region." Said Dr Syafiq Asnawi, Senior Lecturer in Biomedical Science and Director of the Department of Molecular Epidemiology & Translational Medicine and the MUM Proteomics & Metabolomics Platform.

"At Agilent, we support Monash University in enhancing biological research through proteomics, metabolomics and lipidomics. Our renewed collaboration with Monash University Malaysia continues our 15-year collaboration and positions Agilent as a leader in biotechnology innovation. The BioDiscovery Hub will drive scientific progress, talent development, and creating long-term value for customers and partners," said Bharat Bhardwaj, Agilent's vice president of Sales for Asia Pacific.

With more than 25 years of presence in Malaysia, Agilent continues contributing to the nation's scientific landscape, helping drive national progress through academic-industry partnerships and workforce development, and reinforcing Malaysia's position as a growing hub for analytical and biotechnological innovation across the region.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent's full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.95 billion in fiscal year 2025 and employs approximately 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.

Media Contacts

Grace Thong

Agilent Technologies                                                                           

+65 9688 2152

grace.thong@agilent.com 

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/agilent-and-monash-university-malaysia-mark-15-year-partnership-with-new-biodiscovery-hub-to-drive-regional-biotech-innovation-302632782.html

SOURCE Agilent Technologies

Research focuses on human cardiac organoids to uncover metabolic drivers of heart failure and accelerate new therapeutic strategies to improve cardiovascular outcomes

SINGAPORE, Nov. 13, 2025 /PRNewswire/ -- Agilent Technologies Inc. (NYSE: A) announced the signing of a five-year Memorandum of Understanding (MOU) with National Heart Centre Singapore (NHCS) to accelerate innovation in metabolic heart failure research, one of the most complex and underserved areas in cardiovascular medicine.

Heart failure remains a leading global cause of death and disability¹, with metabolic forms such as diabetic heart failure and heart failure with preserved ejection fraction (HFpEF) posing challenges due to limited treatment options². Under this agreement, Agilent and NHCS will combine their expertise in human cardiac organoids using human-derived heart tissues with cutting-edge analytical technologies, including Agilent's latest Seahorse XF Flex Analyzer which expands real-time metabolic analysis into 3D tissues and organoid workflows to investigate metabolic drivers of heart failure.

"Our collaboration with Agilent allows us to advance the study of heart disease using patient-specific beating heart cells. By combining NHCS's expertise with Agilent's advanced technology, we can detect the earliest changes in how heart cells use energy before visible damage occurs. This accelerates the discovery of new therapies and safely testing them, ultimately offering hope to heart failure patients who currently have limited treatment options," said Prof Derek Hausenloy, director of the National Heart Research Institute Singapore (NHRIS) at NHCS.

NHCS has established itself as a leader in modelling monogenic cardiac diseases using patient-specific induced pluripotent stem cells (iPSCs), which led to novel therapeutic targets now undergoing clinical evaluation³^,⁴. Building on this foundation, the integration of Agilent's next-generation technology and NHCS's Preclinical Platform for Development of Therapeutics for Heart Failure (PREVENT-HF) positions the collaboration to provide hypotheses for clinical validation, offering new insights into disease progression, novel therapeutic development, and assessment of treatment safety and efficacy in clinically relevant models.

"Together with NHCS, we are bridging science and technology to reimagine how metabolic heart failure is understood and treated through translational research. This partnership reflects our shared commitment to addressing the unmet needs in cardiovascular care while strengthening our leadership in the biomedical ecosystem, positioning us at the frontier of cardiovascular research locally, regionally, and globally." Said Bharat Bhardwaj, vice president of APAC sales at Agilent.

Over the past decade, Agilent has made significant contributions to research advancement aimed at improving population health in Singapore. In 2019, the National University of Singapore (NUS), National University Hospital (NUH), and Agilent launched a $38 million research hub to boost clinical diagnostics and biochemistry testing.

Last year, Agilent partnered with NUS, acting through the Yong Loo Lin School of Medicine (NUS Medicine), established the NUS-Agilent Center of Excellence in Cell Metabolism in support of the Singapore Ministry of Health's Project RESET, Cardiovascular Metabolic Disease Translational Research Programme (CVMD-TRP) and PREVENT-HF to accelerate the discovery of novel insights into the complex mechanisms of heart disease.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent's full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.51 billion in fiscal year 2024 and employs approximately 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.

About the National Heart Centre Singapore

The National Heart Centre Singapore (NHCS) is a leading national and regional referral centre for cardiovascular diseases, offering 185 beds and a comprehensive range of cardiac care services from preventive to rehabilitative. Ranked #12 as the World's Best Cardiology Hospital by Newsweek 2025, NHCS's clinical outcomes are consistently recognized at the international level, meeting or exceeding global standards. It is also the only facility in Singapore providing heart and lung transplantation programme.

As an academic medical centre, NHCS is committed to training healthcare professionals and advancing cardiovascular health through cutting-edge translational research in collaboration with local and international collaborators.

For more information, please visit: www.nhcs.com.sg

Media Contacts

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/agilent-and-national-heart-centre-singapore-sign-agreement-to-advance-metabolic-heart-failure-research-302613983.html

SOURCE Agilent Technologies